CARLSBAD, California, November 5 /PRNewswire/ --
- Ablation Frontiers, Inc. Participates in the Heart Rhythm Congress 2007 Live EP Cases in Birmingham, UK
Ablation Frontiers, Inc., a privately-held medical device company, announced today its successful first public broadcast of a procedure using the company's novel Catheter Ablation System on October 31. Performed by Dr. Lucas Boersma of the St. Antonius Hospital in Nieuwegein, The Netherlands, the System was used to isolate heart tissue causing a potentially dangerous irregular heart rhythm. The process was transmitted to an audience of heart specialists in Birmingham, United Kingdom, as part of the 2007 Heart Rhythm Congress. Professor John Morgan of the Southampton General Hospital -- a member of the Heart Rhythm Congress organizing committee -- accompanied Dr. Boersma in performing the procedure.
The 60-year old male patient was diagnosed with paroxysmal atrial fibrillation (AF), a recurrent electrical "short circuit" in one of the upper heart chambers, approximately 2 years ago. In March 2007, however, his diagnosis worsened to persistent atrial fibrillation, defined as AF which is sustained beyond seven days. He has suffered from episodic heart palpitations and dyspnea -- all common symptoms of this arrhythmia. "I would often be out of breath and sometimes feel my heart beating much faster than normal," said the patient.
The minimally-invasive procedure was performed in the Cardiac Catheterization Laboratory. Dr. Boersma began by inserting the Pulmonary Vein Ablation Catheter (PVAC(TM)) into the patient's right leg and maneuvering up to the heart by way of a large vein. The multi-electrode circular tip catheter was used to diagnose and treat the cardiac tissue responsible for the irregular heart rhythm, which was located in the left atrium of the heart, near the pulmonary veins. Simultaneously applying radiofrequency (RF) energy to all of the electrodes with the Ablation Frontiers GENius(TM) generator, Dr Boersma created a number of circular "lesions" that blocked the short circuit -- a procedure known as Pulmonary Vein Isolation or PVI. The patient left the Catheterization Laboratory with a normal heart rhythm.
During the procedure, Dr. Boersma isolated all four pulmonary veins in approximately 38 minutes, or 50 minutes from the first venous access. Afterwards he commented, "With this game changing technology I can create a contiguous, circular lesion without having to drag the catheter along the surface of the heart. This greatly simplifies a once complex procedure. The novel design also allows me to perform the procedure with a single catheter for mapping and ablation. After having treated many patients with this technology I have documented substantially reduced procedure times as well as reduced complications from what I would normally expect to see." On Tuesday, the day before the procedure, Dr Boersma presented his results with the PVAC as part of a presentation entitled, "New developments and insights into Atrial Fibrillation ablation therapy." In his initial experience, Dr. Boersma reported 100% acute success -- confirmed pulmonary vein isolation -- with an average total procedure time of 96 minutes.
Professor Morgan noted, "We have successfully used this catheter in a large number of patients at Southampton General Hospital and experienced reduced procedure times without any major complications. We are very happy with the design of both the catheter technology and the RF generator."
Ablation Frontiers has been distributing the PVAC and GENius(TM) RF Generator to a select number of European centers since receiving the CE Mark in December 2006. As part of the company's "toolbox" approach for ablation of all types of arrhythmias, Ablation Frontiers also distributes the Multi-Array Ablation Catheter(TM) (MAAC), Multi-Array Septal Catheter(TM) (MASC), and Tip-Versatile Ablation Catheter(TM) (T-VAC).
Atrial fibrillation remains the most commonly diagnosed cardiac arrhythmia, or irregular heart rhythm, affecting approximately ten million people worldwide. Because AF is a disease that increases with advancing age, with an estimated six percent of the current U.S. population over age 60 and ten percent of the population over age 80 affected by the condition, and the increasing average age of the U.S. population, it is likely that the incidence of AF will more than double over the next several decades. AF is a leading cause of stroke and when left untreated can significantly affect quality of life and lead to stroke, heart failure and death.
Federal Law limits these devices to investigational use in the United States.
About Ablation Frontiers
Ablation Frontiers is an emerging, venture-backed medical device company based in Carlsbad, California. Founded in 2004, the company is focused on developing and commercializing innovative products for the treatment of cardiac arrhythmias. In late 2006, Ablation Frontiers received the CE Mark and actively markets its portfolio of novel anatomical-based catheters and a multi-channel RF generator in the European Union and other international markets. To learn more about the company, visit http://www.ablationfrontiers.com
About the Heartbeat Education Centre
The Live Cases were hosted by the Heartbeat Education Centre, Southampton, which is equipped with high specification audiovisual facilities. This capability enables simultaneous transmission of multiple "screenshots" from up to 7 catheter laboratory suites with simple and effective mechanisms for audience-operator interaction and participation. The demonstrations were intended to show the physician audience in Birmingham some of the newest technologies available for atrial fibrillation (AF) ablation.
Web site: http://www.ablationfrontiers.com
Jay Kelley of Ablation Frontiers, Inc., +1-760-438-4868, ext., 156, email@example.com